A Phase 2 Pilot Study to Characterize and Examine the Pharmacokinetics and Disease Bio-marker Response of Chronocort® in Adults With Congenital Adrenal Hyperplasia
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
研究概览
简要总结
The purpose of this study is to gather safety and effectiveness information about a new formulation of Hydrocortisone (Chronocort®) used to treat patients with a disease called congenital adrenal hyperplasia (CAH). Hydrocortisone is the man-made version of the hormone cortisol, which is released in the body following a regular daily pattern. The objective of the study is to measure the levels of hydrocortisone that are absorbed into the bloodstream once Chronocort® is taken and what affects it has on other hormones in the body. Since Chronocort® is anticipated to mimic the same release pattern of cortisol in the body, it is hoped that patients with CAH will be treated more effectively to manage their disease.
详细描述
This study is a Phase 2 pilot study to characterize and examine the pharmacokinetics and efficacy profile of Chronocort® in adults with congenital adrenal hyperplasia (CAH). It is designed as a two-part, single cohort, open label, multiple dose Phase 2 pilot study to: (Part A) characterize and examine the pharmacokinetics (PK) and disease bio-marker behavior following short-term dosing with Chronocort®; and to (Part B) examine the disease control after six months dose titration with Chronocort® in adults with CAH.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Known CAH due to 21-hydroxylase deficiency (classic CAH) based on hormonal and genetic testing currently treated with hydrocortisone, prednisone, prednisolone or dexamethasone on a stable dosage for a minimum of 3 months.
- •Male or female patients aged 18 and above.
- •Provision of signed written informed consent.
- •Good general health.
- •Females of childbearing potential must have a negative pregnancy test initially and at all visits. Females who are engaging in sexual intercourse must be using a medically acceptable method of contraception (as defined in the protocol, section 10.5).
- •Plasma renin activity must be within the clinically acceptable range at screening (less than 1.5 times upper normal range).
排除标准
- •Co-morbid condition requiring daily administration of a medication that induces hepatic enzymes or interferes with the metabolism of glucocorticoids.
- •Clinical or biochemical evidence of hepatic or renal disease. Creatinine above the normal range or elevated liver function tests (ALT or AST) > 2 times the upper limits of normal.
- •Females who are pregnant or lactating.
- •Women taking an estrogen-containing oral contraceptive pill and who have taken it within 6 weeks of recruitment.
- •Patients taking spironolactone.
- •Patients on inhaled or oral steroids apart from treatment for CAH.
- •Patients with any other significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the trial.
- •Participation in another clinical trial of an investigational or licensed drug or device within the 3 months prior to inclusion in this study.
- •Patients with history of bilateral adrenalectomy.
研究组 & 干预措施
Hydrocortisone Modified Release Capsules
Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
干预措施: Hydrocortisone Modified Release Capsules (Drug)
结局指标
主要结局
Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
时间窗: 24 hours
The maximum plasma concentration (Cmax) of chronocort
Pharmacokinetic Profile (AUC0-24) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
时间窗: 24 hours (at 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)
Area under the curve (AUC) from 0 to 24 hours (sampling occurs at the following timepoints: 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)
Pharmacokinetic Profile (Tmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia
时间窗: 24 hours
Time to maximum plasma concentration (tmax)
次要结局
- Androstenedione Levels at 0700h, 1700h and 2300h(Specified time points (0700h, 1700h and 2300h))
- ACTH Levels at 0700h, 1700h and 2300h(Specified time points (0700h, 1700h and 2300h))
- 17-OHP Levels at 0700h, 1700h and 2300h(Specified time points (0700h, 1700h and 2300h))
- AUC Values (Nmol*h/L) for 17-OHP(Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h))
- The Percentage of Patients With 17-OHP and Androstenedione Levels at 0700h Within Proposed Optimal Ranges Whilst on Chronocort and Whilst on Standard Therapy (at Baseline)(Specific time point (0700hrs))
- AUC Values (Nmol*h/L) for Androstenedione(Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h))
- AUC Values (Pmol*h/L) for ACTH(Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h))